{"a":[{"_":"Merck stages expanded access to monthly HIV PrEP pill ahead of approval","$":{"href":"/pharma/merck-prepares-expanded-access-alimatravir-monthly-hiv-prep-pill-ahead-approval","hreflang":"en"}}]}

PartnershipalimatravirPositive

AI Analysis

Summary

Merck has signed voluntary licensing agreements to provide expanded access to its investigational monthly HIV PrEP pill alimatravir prior to any regulatory submissions, following Gilead's strategy in the market.

Outcome Details

Merck signed voluntary licensing agreements to enable expanded access to investigational alimatravir ahead of regulatory submissions

Importance:5/10

Sentiment:

0.30

HIVPrEPexpanded accesslicensing agreementinvestigational drug

Related Companies

$MRK

Read the original article

Published by FiercePharma on July 24, 2026 9:35 AM

Read Original